Allergan pulls textured breast implants from market

Allergan is recalling its Biocell textured breast implants and expanders in all markets after an FDA request to pull them from the market over safety concerns. 

The affected products will no longer be distributed or sold in any market where they are now available. 

The textured breast implants have been linked to a rare form of cancer, known as breast implant-associated anaplastic large cell lymphoma. 

"Effective immediately, healthcare providers should no longer implant new Biocell textured breast implants and tissue expanders, and unused products should be returned to Allergan," the company announced in its recall notice. 

The recall affects several Biocell products, including natrelle saline-filled breast implants, natrelle silicone-filled breast implants, natrelle inspira silicone-filled breast implants and natrelle 410 highly cohesive anatomically shaped silicone-filled breast implants.

The recall includes tissue expanders used by patients before breast augmentation surgery, including the natrelle 133 plus tissue expander and natrelle 133 tissue expander with suture tabs. 

The recall doesn't affect nontextured implants, the company said. 

More articles on supply chain:
Medline co-founder James Mills dead at 82
Top 5 supply chain stories in June
Philadelphia hospital isn't restocking necessary patient supplies, nurses say

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months